Paper Details

  1. Home
  2. Paper Details

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.

Author: BrownDeborah D, HaberBarbara A, KlopferStephanie O, KwoPaul, NangiaGayatri, ReddyK Rajender, RobertsonMichael N, VierlingJohn M

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Elbasvir/grazoprevir is a safe treatment option for individuals with chronic hepatitis C virus (HCV) infection. It is effective for genotypes 1 and 4, even in individuals with challenging comorbidities like chronic kidney disease or inherited blood disorders. While the drug is generally safe, some side effects may occur at higher frequencies when combined with ribavirin.
Paper Details　
Original Abstract of the Article :
Direct-acting antiviral treatments for chronic hepatitis C virus (HCV) infection are generally safe; however, understanding the safety profile of each regimen is essential for their continued use. Safety data were pooled from 12 clinical trials of elbasvir/grazoprevir (EBR/GZR) that enrolled adult p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.13357

データ提供：米国国立医学図書館（NLM）

Safety and Tolerability of Elbasvir/Grazoprevir for Hepatitis C

The field of hepatology continues to make strides in developing effective treatments for chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens, such as elbasvir/grazoprevir (EBR/GZR), have shown promise in treating HCV. This study, focusing on antiviral therapy, examines the safety and tolerability of EBR/GZR in patients with HCV infection.

Safety Profile of Elbasvir/Grazoprevir

The study, an integrated analysis of data from multiple clinical trials, reveals that EBR/GZR is generally safe and well-tolerated in patients with HCV infection. The most frequent adverse events were headache, fatigue, nasopharyngitis, nausea, and diarrhea. The study also suggests that EBR/GZR appears to be safe in patients with comorbidities, such as chronic kidney disease, inherited blood disorders, or those receiving opioid agonist therapy. This research provides valuable information about the safety profile of EBR/GZR for treating HCV infection.

The Importance of Safe and Effective Antiviral Treatment

This study underscores the importance of understanding the safety and tolerability of antiviral therapies for managing HCV infection. It highlights the potential of EBR/GZR as a safe and effective treatment option for individuals with HCV genotype 1 or 4 infections, even in the presence of comorbidities. This research encourages continued efforts to develop and evaluate antiviral therapies for HCV infection to ensure optimal outcomes for patients.

Dr.Camel's Conclusion

Think of it like a camel navigating a treacherous desert, seeking a safe haven. This research provides valuable insights into the safety of EBR/GZR, a potential oasis in the midst of the challenging journey of managing HCV infection. Understanding the safety profile of antiviral treatments is essential for guiding treatment decisions and ensuring the well-being of patients battling this complex disease.

Date :
  1. Date Completed 2021-08-25
  2. Date Revised 2022-09-09
Further Info :

Pubmed ID

32594612

DOI: Digital Object Identifier

10.1111/jvh.13357

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.